{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=46", "query": { "intervention": "Placebo Intravenous", "page": 46 }, "page_size": 10 }, "pagination": { "page": 46, "page_size": 10, "total_count": 2347, "total_pages": 235, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=47&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=45&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T08:28:42.492Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00413283", "title": "Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Chemotherapy-Induced Thrombocytopenia", "Non-Small Cell Lung Cancer", "Cancer", "Lung Neoplasms", "Oncology", "Solid Tumors", "Thrombocytopenia" ], "interventions": [ { "name": "Romiplostim", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2006-12", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2013-10-24", "last_synced_at": "2026-10-16T08:28:42.492Z", "location_count": 51, "location_summary": "Glendale, Arizona • Anaheim, California • Los Angeles, California + 22 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00413283" }, { "nct_id": "NCT02663622", "title": "Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "Hematopoietic Stem Cell Transplantation", "Leukemia" ], "interventions": [ { "name": "Efprezimod alfa", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2016-09-19", "completion_date": "2021-05-18", "has_results": true, "last_update_posted_date": "2024-01-23", "last_synced_at": "2026-10-16T08:28:42.492Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02663622" }, { "nct_id": "NCT02439359", "title": "A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)" ], "interventions": [ { "name": "CF-301", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ContraFect", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2015-05", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2020-04-07", "last_synced_at": "2026-10-16T08:28:42.492Z", "location_count": 2, "location_summary": "Lenexa, Kansas • Omaha, Nebraska", "locations": [ { "city": "Lenexa", "state": "Kansas" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02439359" }, { "nct_id": "NCT05721287", "title": "A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pain", "Acute Pain" ], "interventions": [ { "name": "SBS-1000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sparian Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "18 Years to 59 Years" }, "enrollment_count": 48, "start_date": "2023-01-30", "completion_date": "2023-08-30", "has_results": false, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-10-16T08:28:42.492Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05721287" }, { "nct_id": "NCT05877963", "title": "Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Ublituximab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TG Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 800, "start_date": "2023-06-13", "completion_date": "2027-01-21", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-16T08:28:42.492Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05877963" }, { "nct_id": "NCT03450707", "title": "Thiamine as a Metabolic Resuscitator After Cardiac Arrest", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cardiac Arrest" ], "interventions": [ { "name": "Thiamine 500 mg IV", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Michael Donnino", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 93, "start_date": "2018-05-06", "completion_date": "2022-02-19", "has_results": true, "last_update_posted_date": "2023-08-24", "last_synced_at": "2026-10-16T08:28:42.492Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03450707" }, { "nct_id": "NCT04001647", "title": "Targeting ER Stress in Vascular Dysfunction", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Vasodilation", "Arterial Stiffness" ], "interventions": [ { "name": "Acetylcholine", "type": "DRUG" }, { "name": "Sodium Nitroprusside", "type": "DRUG" }, { "name": "Ascorbic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Colorado State University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 17, "start_date": "2019-06-01", "completion_date": "2022-08-16", "has_results": false, "last_update_posted_date": "2025-04-08", "last_synced_at": "2026-10-16T08:28:42.492Z", "location_count": 1, "location_summary": "Fort Collins, Colorado", "locations": [ { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04001647" }, { "nct_id": "NCT00973674", "title": "Resuscitative Endocrinology:Single-dose Clinical Uses for Estrogen-Traumatic Brain Injury", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Traumatic Brain Injury" ], "interventions": [ { "name": "Premarin IV", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 50, "start_date": "2009-07", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2019-11-12", "last_synced_at": "2026-10-16T08:28:42.492Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00973674" }, { "nct_id": "NCT06052059", "title": "A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "IV Tulisokibart", "type": "DRUG" }, { "name": "IV Placebo", "type": "DRUG" }, { "name": "SC Tulisokibart", "type": "DRUG" }, { "name": "SC Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "16 Years to 80 Years" }, "enrollment_count": 1109, "start_date": "2023-10-25", "completion_date": "2029-08-01", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-16T08:28:42.492Z", "location_count": 76, "location_summary": "Dothan, Alabama • Fairhope, Alabama • Litchfield Park, Arizona + 65 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06052059" }, { "nct_id": "NCT00110708", "title": "Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism", "Autistic Disorder", "Child Development Disorders, Pervasive", "Gastrointestinal Diseases", "Signs and Symptoms, Digestive" ], "interventions": [ { "name": "Oralgam (human immunoglobulin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PediaMed Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 120, "start_date": "2005-04", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2006-02-22", "last_synced_at": "2026-10-16T08:28:42.492Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110708" } ] }